Health1 min read

Opinion: STAT+: I’m a cardiologist. I’m a little puzzled about the blockbuster new study on deprescribing statins

By · Via STAT Health · Published by Everything Blog

In short

The STREAM trial presented at the American Heart Association's annual meeting investigated deprescribing statins in older adults lacking a history of stroke or heart attacks. Although initial findings showed stopping statins met the technical noninferiority criteria compared to remaining on the drugs, the outcomes between groups diverged upon closer examination. Patients who were randomized to discontinue their statin regimen fared worse overall. Consequently, the data safety monitoring board advised that patients who stopped taking the medication consult their doctors about restarting it.

Key points

  • Stopping statin therapy led to poorer outcomes for patients despite initial noninferiorit…: Stopping statin therapy led to poorer outcomes for patients despite initial noninferiority findings.
  • The trial's data safety monitoring board urged patients who stopped statins to discuss re…: The trial's data safety monitoring board urged patients who stopped statins to discuss restarting with their physicians.
  • Closer evaluations of clinical trial metrics can reveal divergent outcomes that alter ini…: Closer evaluations of clinical trial metrics can reveal divergent outcomes that alter initial safety conclusions.

Sources checked by our analysis pipeline: 1

At the American Heart Association’s recent annual meeting, the overarching theme coming from the center stage, bathed in Pantone red, was one of high-profile neutral findings.

As I listened to the results of the STREAM trial — which found that older adults without a history of heart attacks or strokes who stopped taking statins didn’t have significantly different outcomes from those who continued taking them — I jotted down that the study continued the theme.

But as the Kaplan-Meier curves were cast onto the screen, something felt off: The curves diverged, rather than stayed together. Theoretically, this scenario can happen in noninferiority studies, where researchers are testing whether an intervention offers similar outcomes compared with a standard. De-prescribing statins in this group, by the expectations set by researchers at the beginning of STREAM, was technically noninferior, but nevertheless, still inferior. The patients randomized to stop taking their statin did worse compared with those who continued. Even the trial’s data safety monitoring board suggested that patients who have stopped their statins should talk to their doctors about resuming their medications.

This…

Health